141 related articles for article (PubMed ID: 16456922)
1. Combo drug therapy beneficial for new cases of multiple myeloma.
Health News; 2006 Feb; 12(2):9. PubMed ID: 16456922
[No Abstract] [Full Text] [Related]
2. Thalidomide with continuous low-dose dexamethasone for multiple myeloma.
Gardyn J
J Clin Oncol; 2005 Feb; 23(6):1323. PubMed ID: 15718336
[No Abstract] [Full Text] [Related]
3. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
4. Lenalidomide: a new therapy for multiple myeloma.
Palumbo A; Miguel JS; Sonneveld P; Moreau P; Drach J; Morgan G; Einsele H
Cancer Treat Rev; 2008 May; 34(3):283-91. PubMed ID: 18230411
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in multiple myeloma: current role and future directions.
Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
7. Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
Fukushima T; Nakamura T; Iwao H; Umehara H
Am J Hematol; 2011 Oct; 86(10):893. PubMed ID: 21812018
[No Abstract] [Full Text] [Related]
8. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
Ural AU; Avcu F
Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715
[No Abstract] [Full Text] [Related]
9. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
10. Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
San-Miguel JF
Blood Rev; 2010 Nov; 24 Suppl 1():S1-3. PubMed ID: 21126631
[No Abstract] [Full Text] [Related]
11. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Chim CS
Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
[No Abstract] [Full Text] [Related]
12. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation.
Blade J
Haematologica; 2005 Dec; 90(12):1589. PubMed ID: 16330426
[No Abstract] [Full Text] [Related]
14. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
[TBL] [Abstract][Full Text] [Related]
15. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
Ballester O
Cancer Invest; 2008 Jun; 26(5):445-7. PubMed ID: 18568765
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Morgan GJ; Schey SA; Wu P; Srikanth M; Phekoo KJ; Jenner M; Davies FE
Br J Haematol; 2007 May; 137(3):268-9. PubMed ID: 17408469
[No Abstract] [Full Text] [Related]
17. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
[TBL] [Abstract][Full Text] [Related]
18. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
[No Abstract] [Full Text] [Related]
19. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
Ramasamy K; Hazel B; Mahmood S; Corderoy S; Schey S
Br J Haematol; 2011 Dec; 155(5):632-4. PubMed ID: 21689088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
